Protease-activated receptor 1 is implicated in irritable bowel syndrome mediators-induced signaling to thoracic human sensory neurons

Cleo Desormeaux, Tereza Bautzova, Sonia Garcia-Caraballo, Corinne Rolland, Maria Raffaella Barbaro, Stuart Brierley, Giovanni Barbara, Nathalie Vergnolle, Nicolas Cenac

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Abstract

Proteases and protease-activated receptors (PARs) are major mediators involved in irritable bowel syndrome (IBS). Our objectives were to decipher the expression and functionality (calcium signaling) of PARs in human dorsal root ganglia (DRG) neurons and to define mechanisms involved in human sensory neuron signaling by IBS patient mediators. Human thoracic DRG were obtained from the national disease resource interchange. Expression of PAR 1 , PAR 2 , and PAR 4 was assessed by immunohistochemistry and quantitative reverse transcription PCR (RT-qPCR) in whole DRG or in primary cultures of isolated neurons. Calcium signaling in response to PAR agonist peptides (PAR-AP), their inactive peptides (PAR-IP), thrombin (10 U/mL), supernatants from colonic biopsies of patients with IBS, or healthy controls, with or without PAR 1 or PAR 4 antagonist were studied in cultured human DRG neurons. PAR 1 , PAR 2 , and PAR 4 were all expressed in human DRG, respectively, in 20%, 40%, and 40% of the sensory neurons. PAR 1 -AP increased intracellular calcium concentration in a dose-dependent manner. This increase was inhibited by PAR 1 antagonism. By contrast, PAR 2 -AP, PAR 4 -AP, and PAR-IP did not cause calcium mobilization. PAR 1 -AP-induced calcium flux was significantly reduced by preincubation with PAR 4 -AP, but not with PAR 2 -AP. Thrombin increased calcium flux, which was inhibited by a PAR 1 antagonist and increased by a PAR 4 antagonist. Supernatants from colonic biopsies of patients with IBS induced calcium flux in human sensory neurons compared with healthy controls, and this induction was reversed by a PAR 1 antagonist. Taken together, our results highlight that PAR 1 antagonism should be investigated as a new therapeutic target for IBS symptoms.

Original languageEnglish
Pages (from-to)1257-1267
Number of pages11
JournalPain
Volume159
Issue number7
DOIs
Publication statusPublished or Issued - 1 Jul 2018

Keywords

  • Human dorsal root ganglia neurons
  • Inflammation
  • Irritable bowel syndrome
  • PARs
  • Proteases
  • Thrombin
  • Visceral hypersensivity
  • Visceral pain

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this